Please login to the form below

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer

Data presented at the 2020 European Society for Medical Oncology (ESMO) virtual congress detailed a 40% reduction in the risk of death among previously untreated RCC patients receiving Opdivo plus Cabometyx ... The combination also met the primary trial

Latest news

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... plus tyrosine kinase inhibitor (TKI)
Revenue growth at Ipsen numbs pain of palovarotene calamity

The French speciality drugmaker posted 2.58bn in sales for the full-year, up nearly 15%, thanks to another strong performance for cancer drugs Somatuline (lanreotide) and Cabometyx (cabozantinib) as well ... The company is waiting for phase 3 results for
Exelixis bounces back with new prostate cancer data

It is also approved for use under the name Cabometyx in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) – net product revenues from the entire franchise are expected to be between
Merck bulks up in cancer with $2.2bn Peloton buy

with Exelixis/Ipsen’s multikinase inhibitor Cabometyx (cabozantinib).
Merck’s Bavencio joins first-line kidney cancer face-off

Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the ... Cabometyx has made big gains in

More from news
Approximately 6 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Charting a course for expansion

The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Director – Creative Healthcare Communications: Competative

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Lead Copywriter: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Medical Editor: Competitive

Healthcare Account Director: Competitive

Healthcare Senior Account Manager: Competitive

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

The pandemic preparedness paradox: Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...